Crizotinib offers survival benefits over standard chemotherapy in patients with ALK-positive lung cancer

Crizotinib improves survival in patients with anaplastic lymphoma kinase (ALK) gene, present in 3–5% of non–small-cell lung cancers (NSCLCs) (pictured), research finds

Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3–5% of non–small-cell lung cancers (NSCLCs). Data from an ongoing phase III study indicate that patients with ALK-positive NSCLCs fare better when treated with the ALK inhibitor crizotinib than with standard chemotherapy.

PROFILE 1014 is an open-label study in 343 patients with treatment-naïve, advanced ALK-positive nonsquamous NSCLC given either oral crizotinib or intravenous pemetrexed/platinum chemotherapy.

Interim results published in The
New England Journal of Medicine (online, 4 December 2014)[1]
reveal that crizotinib was associated with significantly longer progression-free survival, significantly higher response rates, a greater reduction in lung cancer symptoms and greater improvement in quality of life. The most common adverse events with crizotinib were vision disorders, diarrhoea, nausea and oedema.

References

 

[1] Solomon BJ, Mok T, Kim D-W et al. First-Line crizotinib versus chemotherapy in ALK-positive lung cancer. The New England Journal Medicine 2014;371:2167-2177. doi: 10.1056/NEJMoa1408440.

Last updated
Citation
The Pharmaceutical Journal, PJ, 3/10 January 2015, Vol 294, No 7843/4;294(7843/4):DOI:10.1211/PJ.2014.20067444